Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Disease Management to Improve Alopecia Areata Quality of CareRelease Date:Quality Improvement Inflammation & Immunology China Driving Timely Biomarker Testing to Optimize Treatment Decisions for Colorectal Cancer Patients Across CanadaRelease Date:Partner: Colorectal Cancer Canada (CCC)Quality Improvement, Research Oncology Canada Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) TherapyRelease Date:Education Oncology Canada Advances in Migraine ManagementRelease Date:Education Internal Medicine USA Optimizing Atopic Dermatitis Quality of Care and Best Practice at Local LevelRelease Date:Quality Improvement Inflammation & Immunology China Use of AI to Improve Speed/Precision of Treatment Selection & Clinical Management for Patients w/ Invasive Mold InfectionsRelease Date:Education Hospital Australia, China, France, Germany, Italy, Korea, Spain, Taiwan, United Kingdom Quality improvement strategies to enhance quality of life in ALK-positive lung cancer patientsRelease Date:Quality Improvement Oncology Spain Efforts to Improve Quality of Migraine CareRelease Date:Partner: The Japanese Headache SocietyQuality Improvement Internal Medicine Japan Maintenance Therapy in HER2+ Metastatic Breast Cancer (MBC)Release Date:Education Oncology USA Title Grant Type Focus Area Country Application Due Date Enhancing HCPs’ Preparedness: Maternal Immunization Knowledge UpdatesRelease Date:Education Vaccines USA Real-World Clinical Outcomes Among Adult and Adolescent Patients with Severe Alopecia Areata Receiving Ritlecitinib in ChinaRelease Date:Research Inflammation & Immunology China Education on the Appropriate Diagnosis and Treatment of Overactive Bladder or Neurogenic BladderRelease Date:Education Internal Medicine Japan Interventional Research Studies with ElranatamabRelease Date:Research Oncology All Research in Ulcerative Colitis (UC) 2024Release Date:Research Inflammation & Immunology Brazil, India, Mexico, Saudi Arabia, Taiwan, Turkey Advances in the Management of Ulcerative Colitis (UC)Release Date:Education Inflammation & Immunology All Research in Ulcerative Colitis (UC) 2024Release Date:Research Inflammation & Immunology Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology USA BCMA-Directed Bispecific Antibody Treatment in Multiple MyelomaRelease Date:Education Oncology Japan Research on MBL producing Enterobacterales and/or Stenotrophomonas maltophiliaRelease Date:Research Hospital Austria, Brazil, China, France, Germany, Greece, India, Italy, Mexico, Saudi Arabia, Spain, Taiwan, Turkey, United Kingdom Increase Awareness & Understanding of Emerging Hemophilia Treatment Options (Global excluding United States)Release Date:Education Rare Disease All Optimal management of patients with prostate cancer receiving androgen deprivation therapy (ADT)Education Oncology USA